Economic evaluation of interventions for treatment-resistant depression: A systematic review

Background The extraordinarily high prevalence of treatment-resistant depression (TRD), coupled with its high economic burden to both healthcare systems and society, underscore how critical it is that resources are managed optimally to address the significant challenge it presents. Objective To review the literature on economic evaluation in TRD systematically, with the aim of informing future studies by identifying key challenges specific to the area, and highlighting good practices. Methods A systematic literature search across seven electronic databases was conducted to identify both within-trial and model-based economic evaluations in TRD. Quality of reporting and study design was assessed using the Consensus Health Economic Criteria (CHEC). A narrative synthesis was conducted. Results We identified 31 evaluations, including 11 conducted alongside a clinical trial and 20 model-based evaluations. There was considerable heterogeneity in the definition of treatment-resistant depression, although with a trend for more recent studies to use a definition of inadequate response to two or more antidepressive treatments. A broad range of interventions were considered, including non-pharmacological neuromodulation, pharmacological, psychological, and service-level interventions. Study quality as assessed by CHEC was generally high. Frequently poorly reported items related to discussion of ethical and distributional issues, and model validation. Most evaluations considered comparable core clinical outcomes – encompassing remission, response, and relapse. There was good agreement on the definitions and thresholds for these outcomes, and a relatively small pool of outcome measures were used. Resource criteria used to inform the estimation of direct costs, were reasonably uniform. Predominantly, however, there was a high level of heterogeneity in terms of evaluation design and sophistication, quality of evidence used (particularly health state utility data), time horizon, population considered, and cost perspective. Conclusion Economic evidence for interventions in TRD is underdeveloped, particularly so for service-level interventions. Where evidence does exist, it is hampered by inconsistency in study design, methodological quality, and availability of high quality long-term outcomes evidence. This review identifies a number of key considerations and challenges for the design of future economic evaluations. Recommendations for research and suggestions for good practice are made. Systematic review registration https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=259848&VersionID=1542096, identifier CRD42021259848.

[1]  R. Tamimi,et al.  Econometric Issues in Prospective Economic Evaluations Alongside Clinical Trials: Combining the Nonparametric Bootstrap with Methods that Address Missing Data. , 2022, Epidemiologic reviews.

[2]  D. Freeman,et al.  Appraisal of patient-level health economic models of severe mental illness: systematic review , 2021, The British Journal of Psychiatry.

[3]  S. Pype,et al.  Real-World Treatment Patterns, Outcomes, Resource Utilization and Costs in Treatment-Resistant Major Depressive Disorder: PATTERN, a Retrospective Cohort Study in Belgium , 2021, PharmacoEconomics - Open.

[4]  W. Brouwer,et al.  Instruments to assess quality of life in people with mental health problems: a systematic review and dimension analysis of generic, domain- and disease-specific instruments , 2021, Health and Quality of Life Outcomes.

[5]  Reed J. D. Sorensen,et al.  Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic , 2021, The Lancet.

[6]  J. Swift,et al.  The importance of listening to patient preferences when making mental health care decisions , 2021, World psychiatry : official journal of the World Psychiatric Association.

[7]  M. Roca,et al.  Economic impact of treatment-resistant depression: A retrospective observational study. , 2021, Journal of Affective Disorders.

[8]  P. Greenberg,et al.  The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers , 2021, PharmacoEconomics.

[9]  B. Mickey,et al.  Long-term quality of life in treatment-resistant depression after electroconvulsive therapy. , 2021, Journal of affective disorders.

[10]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[11]  J. Sheehan,et al.  Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression. , 2021, Journal of comparative effectiveness research.

[12]  M. Milne-Ives,et al.  The Effectiveness of Artificial Intelligence Conversational Agents in Health Care: Systematic Review , 2020, Journal of medical Internet research.

[13]  N. Kathirvel Post COVID-19 pandemic mental health challenges , 2020, Asian Journal of Psychiatry.

[14]  S. Saeed,et al.  Past Epidemics, Natural Disasters, COVID19, and Mental Health: Learning from History as we Deal with the Present and Prepare for the Future , 2020, Psychiatric Quarterly.

[15]  R. McIntyre,et al.  Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization. , 2020, Journal of affective disorders.

[16]  D. Soeteman,et al.  Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States. , 2020, Psychiatric services.

[17]  M. Baggaley Value-based healthcare in mental health services , 2020, BJPsych Advances.

[18]  M. Herdman,et al.  Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines , 2020, The European Journal of Health Economics.

[19]  G. Galeazzi,et al.  Digital Interventions for Screening and Treating Common Mental Disorders or Symptoms of Common Mental Illness in Adults: Systematic Review and Meta-analysis , 2020, Journal of medical Internet research.

[20]  C. Stride,et al.  Efficacy and cost-effectiveness of intensive short-term dynamic psychotherapy for treatment resistant depression: 18-Month follow-up of the Halifax depression trial. , 2020, Journal of affective disorders.

[21]  W. Hoffmann,et al.  Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials , 2020, The European Journal of Health Economics.

[22]  M. Knapp,et al.  Economics and mental health: the current scenario , 2020, World psychiatry : official journal of the World Psychiatric Association.

[23]  D. Blumberger,et al.  Management of Treatment-Resistant Depression: Challenges and Strategies , 2020, Neuropsychiatric disease and treatment.

[24]  K. Lohr,et al.  Defining treatment‐resistant depression , 2020, Depression and Anxiety.

[25]  P. Coyte,et al.  Cost–Utility Analysis of Electroconvulsive Therapy and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression in Ontario , 2019, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[26]  B. Rive,et al.  The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study , 2019, BMC Psychiatry.

[27]  T. Lynch,et al.  Refractory depression – cost-effectiveness of radically open dialectical behaviour therapy: findings of economic evaluation of RefraMED trial , 2019, BJPsych Open.

[28]  J. Brophy,et al.  A Non-inferiority Framework for Cost-Effectiveness Analysis , 2019, International Journal of Technology Assessment in Health Care.

[29]  M. Olfson,et al.  Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System. , 2019, Journal of managed care & specialty pharmacy.

[30]  J. Wildman,et al.  Combining Health and Outcomes Beyond Health in Complex Evaluations of Complex Interventions: Suggestions for Economic Evaluation. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[31]  I. Anderson,et al.  Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression , 2019, ClinicoEconomics and outcomes research : CEOR.

[32]  F. Clement,et al.  Current and Common Definitions of Treatment-Resistant Depression: Findings from a Systematic Review and Qualitative Interviews , 2019, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[33]  Stef van Buuren,et al.  Combining multiple imputation and bootstrap in the analysis of cost‐effectiveness trial data , 2018, Statistics in medicine.

[34]  K. Demyttenaere,et al.  The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review , 2018, The international journal of neuropsychopharmacology.

[35]  Esketamine for the Treatment of Treatment-Resistant Depression: Effectiveness and Value Response to Public Comments on Draft Evidence Report , 2019 .

[36]  I. Anderson,et al.  The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature. , 2019, Journal of affective disorders.

[37]  Russell Fulmer,et al.  Using Psychological Artificial Intelligence (Tess) to Relieve Symptoms of Depression and Anxiety: Randomized Controlled Trial , 2018, JMIR mental health.

[38]  T. Lynch,et al.  Radically open dialectical behaviour therapy for refractory depression: the RefraMED RCT , 2018, Efficacy and Mechanism Evaluation.

[39]  T. Peters,et al.  Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. , 2018, Health technology assessment.

[40]  K. Zivin,et al.  Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States , 2018, JAMA psychiatry.

[41]  Y. Zhao,et al.  Cost‐Effectiveness Modeling of Repetitive Transcranial Magnetic Stimulation Compared to Electroconvulsive Therapy for Treatment‐Resistant Depression in Singapore , 2018, Neuromodulation : journal of the International Neuromodulation Society.

[42]  Thomas Kohlmann,et al.  A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D , 2018, PharmacoEconomics.

[43]  H. Akil,et al.  Treatment resistant depression: A multi-scale, systems biology approach , 2018, Neuroscience & Biobehavioral Reviews.

[44]  A. Culyer,et al.  Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays? , 2018, F1000Research.

[45]  A. Young,et al.  Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom. , 2017, Journal of affective disorders.

[46]  Mickaël Hiligsmann,et al.  How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3) , 2016, Expert review of pharmacoeconomics & outcomes research.

[47]  T. Trikalinos,et al.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.

[48]  Richard G. Moore,et al.  Efficacy and cost-effectiveness of a specialist depression service versus usual specialist mental health care to manage persistent depression: a randomised controlled trial. , 2016, The lancet. Psychiatry.

[49]  T. Peters,et al.  Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial. , 2016, The lancet. Psychiatry.

[50]  H. Ravaghi,et al.  Economic evaluation of resistant major depressive disorder treatment in Iranian population: a comparison between repetitive Transcranial Magnetic Stimulation with electroconvulsive , 2016, Medical journal of the Islamic Republic of Iran.

[51]  Franziska Wulf,et al.  Methods For The Economic Evaluation Of Health Care Programmes , 2016 .

[52]  I. Dhalla,et al.  Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: An Economic Analysis. , 2016, Ontario health technology assessment series.

[53]  K. Nguyen,et al.  Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[54]  S. Riedel-Heller,et al.  Cost-Effectiveness of Collaborative Care for the Treatment of Depressive Disorders in Primary Care: A Systematic Review , 2015, PloS one.

[55]  R. Willke,et al.  Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[56]  M. Cowie National Institute for Health and Care Excellence. , 2015, European heart journal.

[57]  L. Vallejo-Torres,et al.  Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model , 2014, Psychological Medicine.

[58]  C. Altar,et al.  A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. , 2014, Psychiatric services.

[59]  S. Paisley,et al.  A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. , 2014, Health technology assessment.

[60]  T. Peters,et al.  Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: economic evaluation of the CoBalT Trial. , 2014, The British journal of psychiatry : the journal of mental science.

[61]  A. Serretti,et al.  Challenging sequential approach to treatment resistant depression: Cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR⁎D) trial , 2013, European Neuropsychopharmacology.

[62]  S. Edwards,et al.  Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. , 2013, Health technology assessment.

[63]  N. Olchanski,et al.  The economic burden of treatment-resistant depression. , 2013, Clinical therapeutics.

[64]  A. Stern,et al.  Repetitive transcranial magnetic stimulation for treatment-resistant depression , 2013 .

[65]  C. Gudex,et al.  Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study , 2012, Quality of Life Research.

[66]  Kim Woodbridge-Dodd Values-based practice in mental health and psychiatry , 2012, Current opinion in psychiatry.

[67]  Murray Krahn,et al.  Conceptualizing a Model , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[68]  J. Birt,et al.  Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review , 2012, Cost Effectiveness and Resource Allocation.

[69]  C. Carswell Measuring and Valuing Health Benefits for Economic Valuation , 2007, PharmacoEconomics.

[70]  Stavros Petrou,et al.  Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting , 2011, BMJ : British Medical Journal.

[71]  A. Cleare,et al.  What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. , 2009, Journal of affective disorders.

[72]  William W. McDonald,et al.  Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis , 2009, Advances in therapy.

[73]  J. Rothwell,et al.  Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: a multi-centre randomised controlled trial. , 2008, Journal of affective disorders.

[74]  M. Knapp,et al.  “The trouble with QALYs…” , 2007, Epidemiology and Psychiatric Sciences.

[75]  M. Aalabaf-Sabaghi Decision modelling for health economic evaluation , 2007, Journal of Epidemiology and Community Health.

[76]  D. Malone A Budget-Impact and Cost-Effectiveness Model for Second-Line Treatment of Major Depression , 2007, Journal of managed care pharmacy : JMCP.

[77]  J. Rothwell,et al.  The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis. , 2007, Health technology assessment.

[78]  D. Kupfer,et al.  Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .

[79]  B. Lebowitz,et al.  Medication augmentation after the failure of SSRIs for depression. , 2006, The New England journal of medicine.

[80]  M. Posternak,et al.  How should remission from depression be defined? The depressed patient's perspective. , 2006, The American journal of psychiatry.

[81]  Elisabeth Fenwick,et al.  A guide to cost-effectiveness acceptability curves. , 2005, The British journal of psychiatry : the journal of mental science.

[82]  H. D. de Vet,et al.  Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria , 2005, International Journal of Technology Assessment in Health Care.

[83]  M. Posternak,et al.  Is the Cutoff to Define Remission on the Hamilton Rating Scale for Depression Too High? , 2005, The Journal of nervous and mental disease.

[84]  Simon Gilbody,et al.  Stepped care in psychological therapies: access, effectiveness and efficiency , 2005, British Journal of Psychiatry.

[85]  M Sculpher,et al.  Health Technology Assessment: Development and Future , 2009 .

[86]  M. George,et al.  Decision Analysis of the Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation Versus Electroconvulsive Therapy for Treatment of Nonpsychotic Severe Depression , 2004, CNS Spectrums.

[87]  P. Kind,et al.  Usefulness of EQ-5D in Assessing Health Status in Primary Care Patients with Major Depressive Disorder , 2004, Health and quality of life outcomes.

[88]  A. Rush,et al.  The cost consequences of treatment-resistant depression. , 2004, The Journal of clinical psychiatry.

[89]  M. Posternak,et al.  Defining remission on the Montgomery-Asberg depression rating scale. , 2004, The Journal of clinical psychiatry.

[90]  P. Sullivan,et al.  A Comparison of the Direct Costs and Cost Effectiveness of Serotonin Reuptake Inhibitors and Associated Adverse Drug Reactions , 2004, CNS drugs.

[91]  Maurizio Fava,et al.  Diagnosis and definition of treatment-resistant depression , 2003, Biological Psychiatry.

[92]  M. Thase,et al.  Research issues in the study of difficult-to-treat depression , 2003, Biological Psychiatry.

[93]  S. Palmer,et al.  Use of cognitive therapy for relapse prevention in chronic depression , 2003, British Journal of Psychiatry.

[94]  T. Gale,et al.  Defining remission by cut off score on the MADRS: selecting the optimal value. , 2002, Journal of affective disorders.

[95]  M. Boyle,et al.  Multiattribute and Single‐Attribute Utility Functions for the Health Utilities Index Mark 3 System , 2002, Medical care.

[96]  W. Katon,et al.  Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. , 2001, The American journal of psychiatry.

[97]  A Briggs,et al.  Economic evaluation and clinical trials: size matters , 2000, BMJ : British Medical Journal.

[98]  M. Boyle,et al.  Cost-utility analysis in depression: the McSad utility measure for depression health states. , 2000, Psychiatric services.

[99]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.

[100]  D A Revicki,et al.  Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. , 1998, Journal of affective disorders.

[101]  Michael C. Bailey,et al.  Cost-Effective Maintenance Treatment of Resistant Geriatric Depression , 1998 .

[102]  S. Wilson Methods for the economic evaluation of health care programmes , 1987 .